mv-nis
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02192775)
Timeline
Indications
Mechanism of action
- Sodium/iodide cotransporterImmunity, active
SLC5A5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mv-nis
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03171493 | Phase 1 | Jun 1, 2017 | Mayo Clinic, Vyriad, Inc. |
| NCT02919449 | Phase 1 | Jan 1, 2017 | Vyriad, Inc. |
| NCT02192775 | Phase 2 | Mar 1, 2015 | Hoosier Cancer Research Network |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vyriad, Inc. | For profit | 2 | 2 | 1 | 2017 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1